China-based AlphaGen Therapeutics completed a multi-million USD Series A round to advance its pipeline of Pb-212 radioligand therapies (RLT). The funding will accelerate clinical development of first-in-class radiopharmaceuticals and expand its AlphaDirect Pb-212 generator platform, which achieved domestic production breakthroughs. AlphaGen's lead candidates target undisclosed solid tumour indications with preliminary clinical data showing promising safety and efficacy.

Founded in 2022, AlphaGen has built an integrated R&D platform spanning radiochemistry, preclinical evaluation and GMP manufacturing. The company’s proprietary technology enables stable Pb-212 production (a key challenge in alpha radiotherapy) and supports end-to-end supply chain localisation. AlphaGen plans to initiate Phase II trials for its lead program in 2026 while advancing additional pipelines for neuroendocrine tumours and prostate cancer.

According to PharmCube's NextBiopharm® database, there exist 37 Pb-212 drug projects globally under development by 24 different companies. Click here to request a free trial for NextBiopharm®.